Mutations in Parkin (PARK2) are the most common genetic cause of early-onset 21
Introduction 39
Parkinson's disease (PD) is the second most common neurodegenerative disease (1) 40 and, although most PD cases are sporadic, a fraction are familial and caused by mutations 41 in different genes (2) . Mutations in the Parkin (PARK2) gene are the most common cause 42 of autosomal recessive early-onset parkinsonism (EOPD) and are believed to result in a 43 loss of Parkin protein function (3). Parkin variants include rearrangements and copy 44 number variations, such as deletions and duplications of exons, as well as single 45 nucleotide variants (SNVs) that cause missense, nonsense, or splice site mutations (4, 5) . 46
Of these, missense variants are the most frequently reported in PD patients (5) and, 47 because they likely impede Parkin protein function rather than disrupting protein 48 expression, may represent viable targets for therapies that enhance Parkin activity. 49
To envisage such genotype-specific therapies, the pathogenicity of the many Parkin 50 variants in the population first needs to be determined. The American College of Medical 51
Genetics and Genomics for Molecular Pathology (ACMG-AMP) has outlined five standard 52 terminologies to describe variants identified in genes that cause Mendelian disorders (6). 53 "Pathogenic" and "likely pathogenic" indicate a clear or very likely disease-causing effect 54 of a variant, respectively. Conversely,"likely benign," and "benign" indicate variants that are 55 not disease-causing. Variants that cannot be assigned to one of these four groups are 56 designated as "uncertain significance". Over 200 Parkin missense variants have been 57 deposited in public repositories (7-10). However, to date, only a minority have been clearly 58 annotated based on formal criteria. 59 6 family members carrying missense variants in Parkin, were examined to assign weighted 103 points as pathogenic or benign to each variant (Supplementary figure 1) . The pathogenic 104 points and benign points were summed-up separately and compared to preset thresholds 105 to assign the variants with one of the five ACMG-AMP categories (Supplementary figure  106 2). 107
From the PD-specific databases, PDmutDB (5, 9) and MDSgene (4, 7), we identified 108 a total of 75 Parkin missense variants reported in PD patients (Figure 1 ). Most were absent 109 or very rare in the control cohorts from the original reports, possibly due to the small sizes 110 of the control cohorts. Therefore, we searched the 75 variants in public population 111 databases and found that 51 of them were reported in dbSNPs (10) and in the Exome 112
Aggregation Consortium (ExAC), including high-quality variant calls across 60,706 human 113 exomes (8) (Figure 1 ). From ExAC, we also found an additional 164 Parkin missense 114 variants ( Figure 1 ). The classification of the missense variants using clinical evidence 115 allowed us to clearly designate thirteen variants with PD as pathogenic or likely pathogenic 116 and ten variants as likely benign or benign (Figure 1) . In contrast, the large number of 117 remaining variants lacked sufficient data to be assigned to either the benign or pathogenic 118 categories and were therefore designated as of uncertain significance (Figure 1) . 119 All ten likely benign or benign variants were reported in both PD patients as well as in 120 general population cohorts (Figure 1, 2A-B ). Thus, we conclude that their presence in 121 8 not performed). Thirteen were reported as homozygous or compound heterozygous in 147 patients ( Figure 3A ). Six of them were absent or rare in the population database (p.C289G, 148 p.K161N, p.C253F, p.C418R, p.W54R, p.E444Q). However, as only one case was found 149 per variant, the total points assigned did not exceed the threshold to designate them as 150 likely pathogenic ( Figure 3A-B) . Seven of them (p.T240M, p.P437L, p.R33Q, p.E310R, 151 p.P37L, p.R234Q and p.D280N) were reported in multiple cases but had somewhat high 152 MAF in ExAC ( Figure 3A ). From segregation analysis (Supplementary figure 1) , p.T240M 153 showed strong segregation with PD in multiple families. It also was reported as compound 154 heterozygous in an unaffected family member (34). Thus, the benign and pathogenic points 155 for p.T240M exceeded the respective thresholds as likely benign or likely pathogenic 156 ( Figure 3B ). The contradictory criteria for benign and pathogenic assigned it as of uncertain 157 significance, suggesting a low-penetrance variant, a genetic modifier or that additional 158 corroborating evidence is require for more definitive assignment (Supplementary figure 2). 159 p.P437L and p.R33Q showed moderate and weak segregation with PD, respectively, and 160 the remaining four variants showed no clear segregation, leaving each below the likely 161 pathogenic threshold ( Figure 3A-B) . 162
Finally, none of the variants found only in the population databases were reported in 163 PD cases to support their pathogenicity ( Figure 3A -B and data not shown when their 164 functional analysis was not performed). However, because their MAFs did not exceed the 165 cutoff for the high range, and none of the variants were found as homozygous in more than 166 two individuals from ExAC, they also lacked enough evidence to be designated as likely 9 benign or benign and were thus designated as variants of uncertain significance (Figure  168 1). 169
Parkin variants can be classified functionally in cells 170
Next, to determine the effects of the variants on Parkin function, we employed a cell-171 based assay to monitor and quantify mitophagy dynamically using fluorescence-activated 172 cell sorting (FACS) in U2OS cells stably expressing inducible mt-Keima, a pH-sensitive 173 fluorescent protein that is targeted to mitochondria and exhibits a large shift in its emission 174 wavelength upon engulfment in the acidic compartment of lysosomes. The cells also 175 transiently expressed either wildtype (WT) Parkin or one of the Parkin variants fused to 176 GFP and the shift in mt-Keima emission was measured upon mitochondrial depolarization 177 with CCCP (Supplementary Figure 3A) . The GFP intensity in untreated cells was also 178 quantified as a measure of steady-state Parkin protein stability (Supplementary Figure 3B) . 179
The level of CCCP induced Parkin-mediated mitophagy and GFP intensity of the Parkin 180 variants were normalized to that of WT Parkin. 181
We analyzed all the variants that were designated clinically as pathogenic or likely 182 pathogenic, benign or likely benign, and an additional twenty-eight variants designated as 183 of uncertain significance. These variants represented the most common missense variants 184 reported in human population from public databases. Moreover, they were reported in 283 185 out of 309 families or unrelated patients in PD-specific databases. The thirteen Parkin 186 variants classified as pathogenic or likely pathogenic based on clinical evidence ( Figure  187 2A and 2B) all showed significantly decreased mitophagy ( Figure 2C ). Seven variants 188 (p.C253Y, p.R42P, p.C441R, p.C212Y, p.C238W, p.V56E and p.R275W) also showed 189 decreased GFP intensity ( Figure 2C ), suggesting reduced protein stability. Of these, all the 190 variants in the R0RBR formed inclusions to different degrees, detected by fluorescence 191 microscopy (Supplementary figure 4) . In contrast, the p.R42P and p.V56E variants in the 192 Ubl domain showed lower overall GFP intensity without visible inclusions. Thus, for a 193 subset of pathogenic and likely pathogenic Parkin variants, the observed defects in 194 mitophagy are likely to stem from abnormal protein folding and reduced protein stability. In 195 contrast, all ten Parkin variants classified as benign and likely benign based on clinical 196 evidence ( Figure 2A and 2B), exhibited similar GFP intensity as WT and most, with three 197 exceptions, also exhibited WT levels of Parkin-mediated mitophagy ( Figure 2C ). p.Q34R 198 and p.A46T displayed decreased mitophagy, whereas p.R334C showed an almost three-199 fold increase ( Figure 2C ). Of the twenty-eight variants classified as of uncertain 200 significance based on clinical evidence ( Figure 3A and 3B), fourteen displayed similar GFP 201 intensity and mitophagy as WT Parkin ( Figure 3C ). Nine displayed impaired mitophagy, 202 three of which also showed decreased GFP intensity. Surprisingly, five variants showed 203 increased mitophagy. 204
The wide range of changes in Parkin levels and mitophagy prompted us to ask whether 205 we could classify the different variants into discrete groups. Variants that significantly 206 decreased Parkin protein levels and mitophagy were assigned to Group 1 ( Figure 4A and 207 Supplementary table 1). Variants that severely (0-30% of WT) or moderately (30-60% of 208 WT) reduced Parkin-mediated mitophagy but that displayed normal protein levels were 209 assigned to Groups 2 and 3, respectively. Group 4 consisted of variants that were similar 210 to WT whereas Group 5 consisted of variants with increased (>140% of WT) Parkin-211 mediated mitophagy. Interestingly, all the pathogenic or likely pathogenic variants, 212 classified based on clinical evidence, were assigned to group 1 or 2 whereas all the benign 213 or likely benign variants fell into group 3, 4, or 5 ( Figure 4B ). In all the PD case reports we 214 analyzed with Parkin variants, almost half displayed normal or hyperactive function, falling 215 into group 4 and 5 ( Figure 4C ). This suggests that caution must be exercised when 216 assigning causality to Parkin variants reported only in case reports as this may lead to an 217 overestimation of the prevalence of Parkin-related PD. 218
We next examined which lines of clinical evidence were most strongly correlated with 219 functional alterations. Among the variants that segregated with PD in families 220 (Supplementary figure 1C ), all but one (p.R33Q) severely altered Parkin function and were 221 assigned to groups 1 or 2 ( Figure 4D -E). However, it is important to note that segregation 222 analysis was only possible in ~30 families, as most reports only involved single cases or 223 case series ( Figure 4F ). Conversely, variants that were reported as homozygotes in ExAC 224 were frequent in Groups 3, 4 and 5 and were not assigned to Groups 1 or 2 ( Figure 4G Next, we devised a scoring scheme, based on Sherloc, to assign benign or pathogenic 235 points (Supplementary figure 6) , according to the functional group to which the Parkin 236 variants were assigned in the cellular assays ( Figure 4 ). The pathogenic points and benign 237 points were then added to the corresponding points from clinical evidence ( Figure 2B , 3B, 238
and Supplementary figure 1) in order to obtain combined pathogenic and benign scores 239 from all evidence for each variant ( Figure 5A and B). 240
Using these combined clinical and functional scores, all the likely pathogenic variants 241 from clinical evidence were reclassified as pathogenic ( Figure 5A ). Additionally, three likely 242 benign variants were reclassified as benign ( Figure 5A ). Most of the variants of uncertain 243 significance were reclassified as likely benign, while six (including p.T240M) were 244 reclassified as pathogenic and 9 remained of uncertain significance ( Figure 5B ). In 245 summary, all the variants that caused functional alterations assigned to groups 1 and 2, as 246 measured in our experimental assay, were reclassified as pathogenic whereas most 247 variants assigned to functional groups 3, 4 and 5 were reclassified as either benign or likely 248 benign ( Figure 5C ). 249 As the structure of Parkin is known, we simulated the effects of variants on the 252 reported crystal structures of Parkin to understand the mechanism underlying the 13 functional change. The autoinhibited Parkin, pUb-bound Parkin, p-Ub-bound phospho-254
Structural analysis of Parkin variants reveals
Parkin, pUb -E2 enzyme-bound phospho-Parkin structures were used as they represented 255
Parkin in different states of activation (19, 20, 35, 36) . 256
Most variants in functional groups 1, 2 and 3 introduced clashes or altered interactions 257 with nearby residues in at least one of the Parkin structures. In contrast, most variants in 258
Group 4, which displayed similar function as WT Parkin, introduced no major clashes and 259 did not affect interactions ( Figure 6A figure 8A and (19, 20) ). p.G284R introduces 280 major clashes with pUb, thus impairing binding and recruitment to mitochondria 281 (Supplementary figure 8B) . p.R275W disrupts interaction with the helix that mediates pUb 282 binding (Supplementary figure 8C ). This would destabilize the protein, and indeed the 283 protein levels of R275W are lower than WT ( Figure 2C ). This helix becomes more exposed 284
following pUb binding and may be involved in the allosteric release of the Ubl (19, 20), and 285
Arg275 was also suggested to bind ubiquitin charged on an E2 enzyme (36), suggesting a 286 combined effect of impaired activation and protein destabilization. The clashes caused by 287 p.R42P and p.V56E are predicted to misfold the Ubl domain and thus destabilize the 288 protein, as demonstrated earlier for p.R42P which was found to be insoluble (25) . 289
Meanwhile they may also hinder conformational change during activation by preventing 290
Ubl phosphorylation and the binding of pUbl on RING0. One variant, p.P437L, introduced 291 very mild clashes in RING2 in the structure, and the exact molecular mechanism of 292 p.P437L in causing decreased mitophagy was unclear. 293
Several variants in functional Group 3 that moderately decreased Parkin-mediated 294 mitophagy might also act by hindering Parkin activation by PINK1. p.A46T could disrupt 295 the interaction of pUbl with RING0 (Supplementary figure 8D ). Arg104 is located in the 296 newly identified activation element (ACT) in the linker (20), which binds RING0 and helps 297 stabilize the interaction with pUbl. p.R104W disrupted a short helix in the ACT and induced 298 clashes with the pUbl (Supplementary figure 8E and (20)). p.G359D disrupted the glycine-299 rich loop in the IBR domain that interacts with pUb (Supplementary figure 8F) . These 300 clashes may be compensated by minor local conformation changes, and thus lead to 301 milder disruptions in mitophagy and protein stability. 302
Structure-guided designer hyperactive Parkin mutants 303 can rescue mitophagy in pathogenic variants 304 We next hypothesized that some of the pathogenic variants may represent targets for 305 genotype-specific therapy. As a proof of concept, we introduced two artificially designed 306 mutations, W403A and F146A, which destabilized the REP (repressor element of 307 Parkin):RING1 and the RING0:RING2 interfaces, respectively. Both of these mutations 308 have been shown to accelerate mitophagy by promoting the conformational changes that 309 occur at these interfaces during Parkin activation by PINK1 (35, 39) . We tested whether 310 these hyperactive mutations could rescue the mitophagy defects seen in the pathogenic 311
Parkin variants. As reported previously, mutating F146A or W403A alone enhanced 312 mitophagy compared to WT Parkin ( Figure 7A ) (14, 35, 39) . Remarkably, introducing 313 F146A or W403A in cis with p.R42P, p.V56E, p.K161N, p.K211N, p.R275W p.P437L or 314 p.T240M rescued mitophagy ( Figure 7A ). Variants p.R42P, p.V56E and p.R275W each 315 lower Parkin levels, likely by disrupting protein stability ( Figure 2C ). However, introduction 316 of F146A or W403A did not restore Parkin levels to WT (Supplementary figure 9) , 317 suggesting the rescue of mitophagy was mediated by Parkin activation per se rather than 318 by enhancing Parkin protein stability. The pathogenic variants p.K161N and p.K211N are 319 involved in binding the pUbl during activation (19, 20) . The fact that both these variants 320 can be rescued by F146A or W403A suggests that destabilization of the REP:RING1 or 321 the RING0:RING2 interface can bypass the tethering of the Ubl to RING0, which occurs 322 during Parkin activation. 323
In contrast, neither F146A nor W403A could rescue any of the 7 pathogenic cysteines 324 variants involved in zinc coordination ( Figure 6C ). This is not surprising as mutating these 325 cysteines are predicted to severely disrupt overall Parkin folding and stability ( Figure 2C Figure 6C ). Not surprisingly, p.G284R also could not be rescued as it disrupts binding to 330 pUb, which is an essential receptor for recruiting Parkin to damaged mitochondria (40). 331
Interestingly, whereas both p.T240M and p.T240R are predicted to interfere with E2 Ub-332 conjugating enzyme binding to RING1 ( Figure 6C ) and showed similar severe defects in 333 mitophagy ( Figure 2C and 3C), only the former could be rescued by F146A or W403A 334 ( Figure 7A ). Both variants created clashes in the E2 binding site (Supplementary figure 10) . 335
However, arginine created a positive charge at the interface, increasing the electrostatic 336 repulsion of E2. Methionine is less bulky and neutral, and its flexibility could allow some 337 weak interactions with E2 to remain, perhaps explaining its rescue by F146A or W403A. 338
Overall, the defects in mitophagy of seven of the 19 pathogenic variants could be 339 rescued by the designed activating mutations. These seven variants are responsible for 340 over 75% of reported PD patients carrying pathogenic missense variants ( Figure 7B) and 341
were the most frequent pathogenic missense variants in the general population ( Figure  342   7C ). Mimicking the effects of F146A or W403A could therefore be useful for starting point 343 for designing a treatment for patients with PD caused by these Parkin variants. 344
Characterization of naturally-occurring hyperactive 345
Parkin variants 346 We identified 6 naturally-occurring variants that, considering all the evidence, were 347 classified as likely benign or benign and showed enhanced Parkin-mediated mitophagy. 348
The Parkin structure shows that Arg234 and Arg256 are located at the interface between 349 the REP and RING0. The p.R234Q and p.R256C variants are predicted to destabilize the 350 interface, thus mimicking the W403A designer mutant used above ( Supplementary Figure  351 11A). Additionally, p.M458L may destabilize the RING0:RING2 interface, mimicking the 352 effects of our other designer mutation, F146A (Supplementary Figure 11B) . Thus, 3 of the 353 6 naturally-occurring variants are likely to activate Parkin via mechanisms akin to those 354 involved in the hyperactive mutants designed previously, based on structural predictions 355 (39). Because these variants occur naturally in the population, our findings demonstrating 356 rescue of mitophagy suggest that targeting these sites and mechanisms are likely to be 357 tolerated and potentially therapeutic in PD. p.P37L also moderately increased Parkin-358 mediated mitophagy, but the structural basis of the increased activity was unclear, as this 359 variant does not create any steric clash and thus should not affect interactions of the Ubl 360 with RING1 or interactions of the pUbl with RING0 ( Supplementary Figure 11C and 11D) . 361
Mutation of R334 to a cysteine could affect the coordination of a nearby zinc in the IBR, 362 which may stabilize the interaction with phospho-ubiquitin and thereby enhance Parkin 363 activity (Supplementary Figure 11E) . 364
Finally, unlike the 5 other naturally-occurring hyperactive variants, p.V224A has not 365 been reported in PD patient databases and showed the highest (almost 3-fold above WT) 366
Parkin-mediated mitophagy activity ( Figure 3C ). The Val224 residue is localized in the pUb 367 binding pocket, with its side-chain facing towards the phosphorylated Ser65 residue of pUb 368 and the mutation to alanine could modulate the affinity of Parkin for phospho-ubiquitin 369 (Supplementary Figure 11F) . We therefore examined the ability of hyperactive p.V224A to 370 rescue the defects in mitophagy of the pathogenic variants. Introducing the p.V224A 371 variant in cis did not affect the protein level of most pathogenic variants, except for 372 p.G284R ( Figure 8A ). This may stem from an additive destabilizing effect of the double 373 mutant on Parkin folding as both p.V224A and p.G284R are located within the same pUb 374 binding motif. Introducing the p.V224A variant partially rescued the mitophagy defects of 375 p.R42P, p.V56E and p.K161N ( Figure 8B ). How the predicted effects of V224A on pUb-376 binding could partially compensate for defects in Ubl-and pUbl-mediated activation by 377 p.R42P, p.V56E and p.K161N remains to be elucidated. Moreover, the rescue of p.K161N 378 but not p.K211N cannot be easily explained since both are predicted to interfere with pUbl 379 binding (Supplementary figure 7A) and tethering of the Ubl to RING0 during activation (19, 380 20) . Similarly, p.V224A could not rescue the mitophagy deficit in p.R275W and p.G284R 381 variants, predicted to disrupt pUb binding, nor could it rescue any of the remaining 382 pathogenic variants ( Figure 8B) . Thus, compared with F146A or W403A, p.V224A was less 383 effective at rescuing the pathogenic variants, suggesting that the pUb-binding site may be 384 a less promising target than releasing the autoinhibited conformation of Parkin for 385 activating mitophagy. 386
Discussion

387
Parkin mutations are the most common cause of recessive early-onset PD (EOPD) 388
(3). Although Parkin loss-of-function is well established in EOPD (4, 41), causality for any 389
given missense variant has been more difficult to ascertain. In this study, we have 390 integrated clinical, experimental and structural modeling approaches to map out the 391 landscape of Parkin variants in the general population and in PD patients. Our hope is that 392 this work will help provide a more cohesive framework to guide basic science studies 393 exploring the molecular and cellular functions of the PINK1/Parkin pathway and to guide 394 clinicians caring for patients carrying specific Parkin variants. We also hope that the work 395 will inform structure-based drug design to develop Parkin activators and help guide Parkin 396 allele-and genotype-specific clinical studies. 397
For the over 200 Parkin variants reported in public databases (4, 5, 8), we found that 398 only a minority of variants could be clearly designated as likely pathogenic, pathogenic, 399 likely benign or benign based on clinical evidence alone. While this may not seem 400 surprising for variants found only in population databases such as ExAC, where 401 accompanying clinical information is scant, we found a similar situation for variants 402 reported in patients. Indeed, 52 out 75 variants reported in PDmutDB and MDSgene 403 remained of uncertain significance after having been subjected to the Sherloc algorithm, 404 the variant classification framework derived from ACMG standards that we used in this 405 study. The overarching message from these observations is that the mere presence of 406
Parkin variants in PD patients, PD kindreds or PD-specific databases should be interpreted 407 with caution and not automatically taken to imply pathogenicity. Rather, we propose that 408 clinical evidence available for new variants should be subjected to the same rigorous 409 classification scheme presented here to determine pathogenicity. 410
In addition to analyzing clinical evidence, we extensively characterized the cellular 411 effects of the 51 Parkin variants most commonly found in patient and population 412 sequencing databases (Over 90% of all PD patients carrying Parkin missense variants in 413 disease databases; Sum of MAF as 28.177% out 28.533% in ExAC). Using mitophagy and 414 steady-state Parkin protein levels as readouts in a flow cytometry-based assay, we were 415 able to classify the variants into 5 functional groups. To our knowledge, a systematic 416 analysis integrating clinical evidence with cellular function, on this scale, has not been 417 reported previously for Parkin (24) (25) (26) (27) (28) (29) (30) (31) . Notably, all the variants designated as pathogenic 418 or likely pathogenic based on clinical evidence also displayed severe mitophagy defects in 419 cells (functional groups 1 and 2). Conversely, all variants designated clinically as benign or 420 likely benign displayed mitophagy function in the WT range or showed only a slight 421 reduction (functional groups 3, 4 and 5). While this may seem a priori as self-evident, 422 several alternative functions of Parkin in cells have been proposed and the role of 423 mitophagy in PD has yet to be definitively established (21, 22, 42, 43) . Thus, while this 424 work does not refute the biological importance of such alternative functions, the tight 425 correlation between the clinical impact of the variants and their effects on mitophagy 426 provides further evidence that mitophagy can be used as a robust and disease-relevant 427 readout of Parkin function that likely reflects a key pathogenic process in PD. 428
Assignment of the Parkin variants to functional groups in cells allowed us to determine 429 which clinical features best correlate with and could be used to predict pathogenicity. 430
Segregation of variants with PD in families turned out to be very strongly associated with 431 defects in mitophagy, whereas variants that occurred as homozygotes in ExAC never 432 displayed defects in mitophagy in cells. Therefore, we propose that these two clinical 433 criteria be used as strong predictors of pathogenicity of Parkin variants. In contrast, neither 434 the number of variants in PD patients nor the MAF in population databases correlated with 435 cellular function, suggesting that these clinical criteria would not be useful predictors of 436 pathogenicity. Perhaps more importantly, integrating clinical with functional evidence from 437 cells allowed us to re-assign 19 of the 28 variants, designated as of uncertain significance 438 based on clinical evidence alone, to one of the benign and pathogenic categories. It also 439 allowed us to reclassify 6 of the "likely" variants to their respective more definitive benign 440 and pathogenic categories. Together, these findings attest to the power of using this sort 441 of iterative combined clinical and experimental approach to stratify variants. 442
Beyond stratification, given what is already known about the structure and function of 443 the Parkin protein, the work enables in-depth mechanistic exploration of how pathogenic 444 variants can lead to dysfunction. This is something that has been sorely lacking and may 445 have important implication for how best to target Parkin and design activator for future 446 therapy. As one might expect, most missense variants that led to severe defects in all the variants that also led to reduced steady-state Parkin levels (Functional group 1) 449 introduced major clashes, likely leading to protein destabilization and, for several, the 450 formation of inclusions in cells. These inclusions-forming variants occurred in zinc-451 coordinating cysteine residues within RING domains, which are required for proper protein 452
folding. Additional variants are predicted to impede pUb-binding, E2-binding, Ubl folding, 453 the RING0-pUbl interface or Parkin catalytic activity centered around residue C431. In 454 contrast, variants that led to only minor or no changes in Parkin function in cells (Functional 455 groups 3 and 4), for the most part did not introduce clashes or only minor clashes that likely 456 could be tolerated or compensated by local rearrangements in nearby residues. Taken 457 together, the important point is that, for most of the pathogenic variants, the mechanisms 458 by which they interfere with function can be rationalized based on the Parkin structure. 459
As an important proof of concept, we showed that the function of several pathogenic 460
Parkin variants, defective in mitophagy in cells, could be rescued when expressed in cis 461 with mutations that we had previously designed to enhance Parkin activity, based on its 462 structure (35, 39) . Notably, many of the most commonly occurring variants were the ones 463 that could be rescued, something that bodes well for patients carrying these variants, 464
should a therapeutic mimicking W403A or F146A become available. The variants that could 465 be rescued could be stratified according to structure and mechanism. For instance, 466 alterations in residues involved in zinc coordination, in catalytic activation or in pUb-binding 467 could not be rescued. In contrasts, alterations in residues involved in Ubl folding or in the to only a minor defect in mitophagy. Together, these data suggest that binding of the pUbl 471 to RING0, as seen in the recent crystal structures of the active configuration of Parkin (19, 472 20) , may not be absolutely required for activation and could potentially be bypassed by a 473 therapeutic that disrupted the REP-RING1 or the RING0-RING2 interfaces. Interestingly, 474 both p.T240R and p.T240M variants in the E2-binding site of RING1, abolish mitophagy in 475 cells. However, while p.T240R could be rescued, p.T240M could not. This likely stems from 476 the additional electrostatic effects of the arginine compared to the methionine substitution 477 in repulsing the E2 enzyme. Congruently with these structural and functional findings 478 suggesting that p.T240R is more severe, clinical evidence led to the assignment of 479 p.T240R as likely pathogenic whereas p.T240M was classified as of uncertain significance. 480
This highlights the importance of carefully considering clinical, functional and structural 481 data for each variant as they may have profound implications, not only for prognosis but 482 also for patient stratification for therapy. 483
One of the most surprising findings of our study was that several naturally-occurring 484 variants exhibited a 1.5-to almost 3-fold enhancement Parkin-mediated mitophagy in our 485 assay. This could not simply be explained by increased Parkin protein levels or by the fact 486 that our assay involved overexpression. Indeed, except for certain pathogenic variants that 487 destabilized Parkin, most variants, including these hyperactive one, displayed steady-state 488 levels that were within a narrow window around WT. These hyperactive variants provide 489 an important proof of principle that there are, presumably healthy, people out there in the 490 population living with enhanced Parkin activity. While all of these variants were classified 491 clinically as either benign or of uncertain significance, because they are so rare, it is unlikely 492 that it will be possible to test at a population level whether they are in fact protective against 493 PD. On a mechanistic level, 3 of the 6 naturally-occurring hyperactive variants likely act by 494 disrupting the REP-RING1 or RING0-RING2 interfaces, similarly to and to the same extent 495 (roughly 1.5-fold) as p.W403A and p.F146A, respectively. These findings add further 496 support to the idea that targeting these sites may be viable strategies for Parkin 497 enhancement. The most strongly activating variant was V224A, which increases mitophagy 498 by nearly 3-fold and occurs very near the site for pUb-binding. This was surprising as pUb-499 binding serves as a critical receptor needed to recruit Parkin to mitochondria and, to date, 500 every reported mutation in this motif, abolished or dramatically reduced mitophagy. 501
Moreover, when expressed in cis, V224A partially rescued certain but not all the mutants 502 that were rescued by W403A and F146A. The mechanism by which V224A enhances 503
Parkin function and rescues defects elsewhere in the protein remain unknown. In the future, 504 it will be important to test whether this involves an enhancement in pUb-binding or some 505 other downstream allosteric effect. Similarly, it will be important to determine the 506 mechanisms by which the two remaining hyperactive variants, P37L and R334C, enhance 507
Parkin function. Moreover, as we only sampled 51 of the over 200 Parkin variants in the 508 population in this study, it is conceivable that other yet-to-be-discovered hyperactive 509 variants will provide further mechanistic insight into Parkin activation and help identify 510 additional therapeutic sites within the protein to target. 511
Materials and methods
514
Classification of Parkin missense variants 515 We utilized Sherloc (semiquantitative, hierarchical evidence-based rules for locus 516 interpretation), a variant classification framework derived from ACMG standards (6) to 517 assign Parkin missense variants into five categories: pathogenic, likely pathogenic, benign, 518 likely benign and of uncertain significance (11). We considered two broad categories of 519 evidence for the classification, clinical and functional. The procedures for evaluating and 520 scoring these lines of evidence are summarized as root-decision trees in Supplementary  521 figures 1,2,6 522
For clinical evidence, information regarding missense variants in Parkin reported in 523 the population database ExAC (http://exac.broadinstitute.org/gene/ENSG00000185345) 524 and the disease-specific databases, PDmutDB (http://www.molgen.vib-ua.be/PDmutDB) 525 (5, 9) , and MDSgene (http://www.mdsgene.org/) (7) were searched. We also searched 526 dbSNP (http://www.ncbi.nlm.nih.gov/snp) and the Exon variant server (EVS, 527 http://evs.gs.washington.edu/EVS/) for missense variants that were found in the disease 528 databases but not in ExAC. The homozygote count, MAF in ExAC and maximal MAF in 529 dbSNP, EVS and subpopulations in ExAC were calculated and used to assign points to the 530 variants according to the decision tree in Supplementary figure 1A . The clinical cases 531 reported in PDmutDB and MDSmutDB were evaluated according to the decision tree in 532
Supplementary figure 1B-C. The original references were traced back for the indexed 533 families or individuals reported in these databases. Indexed cases reported in both 534 databases cited from the same reference were only evaluated once. Indexed cases 535 reported in a more recent paper showing the same information (same number of family 536 members with same genotype and phenotype) as a case in an older reference were 537 considered as the same family and the older report was used. 538
For functional evidence, the effects of the variants in the cellular assay were assigned 539 points according to the decision tree in Supplementary figure 6. We imposed a 2.5-point 540 cap on functional evidence to ensure that functional data which lacked supporting clinical 541 evidence would not be sufficient on its own to reach the threshold required (3 benign points 542 or 4 pathogenic points; supplementary figure 2) to assign a variant into the pathogenic or 543 benign categories (11). 544
Cell culture, cloning and mutagenesis 545
Human osteosarcoma U2OS cells stably expressing GFP-Parkin were a gift from Dr. 546
Robert Screaton (Sunnybrook Research Institute). U2OS cells stably expressing mtKeima 547 were created by transfecting plasmid DNA using jetPRIME (Polyplus), followed by selection 548 with G418 for 2 weeks and sorting using flow cytometry (39). Cells were maintained in 549 DMEM supplemented with 10% fetal bovine serum (FBS), 4mM L-glutamine and 0.1% 550 Penicillin/Streptomycin, in a 37℃ incubator with 5% CO2. All GFP-Parkin variants were 551 generated using PCR mutagenesis according to the manufacturer's protocol (Agilent 552 Technologies). Constructs were verified by sanger sequencing. University). Measurement of mtKeima was made using a dual-excitation ratiometric pH 563 calculation where pH 7 was detected through the excitation at 405nm and pH 4 at 561 nm. 564
For each untreated sample, 75,000 events were collected and single GFP-Parkin-positive 565 cells were subsequently gated for quantification of the geometric mean of the GFP signal 566 as a measure of steady-state Parkin protein levels. The value for each Parkin missense 567 variant was normalized to that for WT in each repeat. For each untreated and treated 568 sample, single GFP-Parkin-positive, mtKeima-405nm-positive cells were subsequently 569 gated. The percentage of cells with an increase in the 405nm:561nm ratio in mtKeima was 570 quantified. The percentage in treated cells minus the percentage in untreated cells was 571 calculated as the induced Parkin-mediated mitophagy. The induced mitophagy for each 572
Parkin missense variant was normalized to that for WT in each repeat. Data was analyzed 573 using FlowJo v10.1 (Tree Star). 574
Modeling of Parkin Structures, Modifications and 575
Variants 576
The structures of human Parkin bound to phospho-ubiquitin (PDB 5N2W), rat parkin (PDB 577 4ZYN), human phospho-parkin bound to phospho-Ub (PDB 6GLC) and fly pParkin-pUb-578
UbcH7 complex (PDB 6DJX) were analyzed using PyMOL version 1.5 (Schrödinger, New 579 York). Mutations and clashes were simulated using the mutagenesis wizard toolbox. The 580 presence of more than three simulated significant clashes (red disks) was taken to indicate 581 major clashes. One to three significant clashes (red disks) together with other slight 582 clashes (brown and green disks) were considered as minor clashes. Polar contacts within 583 4 Å distance of the residue were explored for characterizing interactions. figure 1) , which was then assigned with 1 of 5 standard terminologies using Sherloc (Supplementary figure 2) : Pathogenic (red), likely pathogenic (pink), likely benign (green), benign (olive) and uncertain significance (grey). 
